Effect of Zhuang Medicine Feilongzhangxue on the Expression of HMGB1-TLR4 / RANKL-NF-κB Signaling Pathway Related Factors in Osteoclasts

Objective:To study the regulatory effect of feilongzhangxue on the levels of HMGB1-TLR4/RANKL-NF-κB signaling pathway related factors HMGB1,RANKL,rank,TRAF-6 and NF-κBp65 in osteoclasts,so as to explore the mechanism of feilongzhangxue intervention in RA;Methods:The osteoclasts with good activity were randomly divided into blank group,methotrexate control group and Zhuang medicine feilongzhang blood containing serum treatment group,which were divided into OC+blank group,OC+methotrexate control group,OC+Zhuang medicine feilongzhang blood containing serum group;The expression of HMGB1,RANKL,rank,TRAF-6 and NF-κBp65 mRNA was detected by RT-PCR;The protein expressions of HMGB1,RANKL,RANK,TRAF-6 and NF-κBp65 were detected by immunofluorescence.Results:PCR results showed that:Compared with the blank group,feilongzhangxue could effectively inhibit the expression levels of HMGB1,RANKL,rank,TRAF-6 and NF-κB p65 mRNA in OC cells,and the inhibitory effect was stronger than methotrexate.Immunofluorescence test results showed that:Compared with the blank group and methotrexate group,feilongzhangxue could effectively inhibit the protein expression of HMGB1,RANKL,rank,TRAF-6 and NF-κB p65 in OC cells.Conclusion:The effect of Zhuang medicine feilongzhangxue on hmgbl-tlr4/rankl-nf-κB signaling pathway of osteoclasts is through the regulation of related factors HMGB1,RANKL,rank,TRAF-6 and NF-κB p65,which may be the key mechanism of Zhuang medicine feilongzhangxue on rheumatoid arthritis.